Intercell USA (formerly Iomai) is developing needle-free alternatives to boost your immune system using a transcutaneous method, which delivers vaccines to cells found on the outer layers of the skin. It has a handful of product candidates in development, all in patch form, aimed at preventing seasonal flu and travelers' diarrhea (caused by E. coli, for instance). One of its patches is being funded under a contract from the US Department of Health and Human Services to aid in the treatment of pandemic flu. In 2008 the company was acquired by Austria-based vaccine maker Intercell AG.

Enzon Pharmaceuticals, Inc. company was founded in 1981 and is based in Bridgewater, New Jersey. Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in developing, manufacturing, and commercializing medicines for patients with cancer and other life-threatening conditions in the United States and internationally. Its products include Oncaspar, a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia; and DepoCyt, an injectable chemotherapeutic agent for the treatment of patients with lymphomatous meningitis. The company also offers Abelcet, a lipid formulation of amphotericin B used to treat immuno-compromised patients with invasive fungal infections; and Adagen, a PEGylated bovine adenosine deaminase enzyme (ADA) used to treat patients afflicted with a type of severe combined immunodeficiency disease, which is caused by the chronic deficiency of ADA. In addition, it licenses its PEGylation platform for products, such as PEG-INTRON, Pegasys, Macugen, and CIMZIA; and provides contract manufacturing services for various injectable products.Enzon is also developing PEG-SN38 for the treatment of colorectal, breast, and pancreatic cancer, as well as for non-Hodgkin's lymphoma; and HIF-1 alpha antagonist for the treatment of cancers and common solid tumors. Further, it offers Recombinant Human Mannose-Binding Lectin, a protein therapeutic to prevent and treat severe infections in individuals with low levels of MBL; and provides contract manufacturing services for various injectable products. The company has development and commercialization agreements with Santaris Pharma A/S; Schering-Plough; Sanofi-Aventis; Medac; Micromet; NatImmune A/S; Nektar; Pacira; and Cephalon France SAS. It markets its therapeutic products through its sales force that includes specialists in oncology, hematology, infectious disease, and various critical care disciplines.

Amazon Herb sells herbal supplements and other herbal products through a multilevel marketing network under the Rainforest Bio-Energetics brand. The company buys raw materials harvested by indigenous peoples of the rainforests in Peru; it contracts with third parties to make its products, then it packages them under its own label for sale in the US. Its products include herbal nutritional supplements, skin care products, cleaning supplies, and herbal pet-care remedies. Amazon company also sells raw materials in bulk to other manufacturers and donates 10% of its net profits for rain forest preservation.

Established in 1989 as the commercial arm of the Scottish Crop Research Institute, MRS assists UK agricultural and plant biotechology scientists develop their ideas into marketable products. Profits earned from its efforts are plowed back into the research institution. MRS labs offer pathogen testing, plant analysis, and consulting services. MRS works with companies interested in licensing technologies that the researchers use to breed high-quality varieties of potatoes, soft fruits, barley, and other agricultural products.

Skystar Bio-pharmaceutical Company ("Skystar") is one of China's leading manufacturers and distributors of vaccines and medicines for poultry, livestock and domestic pets. Skystar has over 173 products in its current product line and has over 50 more products in development. Skystar employs over 200 people in Production Facilities located in Hu Xian, Xi'an City, Shaanxi, Province, PRC.Skystar has recently opened (July of 2006) its new GMP Certified Facility that will increase production capabilities by 200%. The demand for veterinary medicines and vaccines in China far exceeds the supply and Skystar's plan is to capitalize on its new GMP Certified Facility to increase margins while increasing production to help meet the growing and overwhelming demand for its products.

Dr. Reddy’s Laboratories Limited (Dr. Reddy’s) is a global pharmaceutical company. The Company operates in three segments: Pharmaceutical Services and Active Ingredients (PSAI), which includes active pharmaceutical ingredients and intermediaries, which are the principal ingredients for finished pharmaceutical products; Global Generics, which consists of finished pharmaceutical products ready for consumption by the patient, and Proprietary Products, which involves the discovery of new chemical entities for subsequent commercialization and out-licensing. Dr. Reddy’s is vertically integrated and uses its pharmaceutical ingredients and intermediates in its own finished dosage products. The Company conducts basic research mainly in the areas of metabolic disorders, cardiovascular diseases and bacterial infection. On July 30, 2008, it acquired 85.69% interest in Perlecan Pharma Private Limited (Perlecan Pharma). Subsequently Perlecan Pharma became a wholly owned subsidiary of the Company.

Molecular Insight Pharmaceuticals was founded in 1997 and is based in Cambridge, Massachusetts. Molecular Insight Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the research, development, and commercialization of molecular imaging pharmaceuticals and radiotherapeutics primarily in the areas of oncology and cardiology in the United States. The company develops Zemiva, a molecular imaging pharmaceutical product, which completed Phase II clinical trail for the diagnosis of cardiac ischemia or insufficient blood flow to the heart; and Trofex, a preclinical trail product for the detection of metastatic prostate cancer. Its molecular radiotherapeutic oncology product candidates under development include Azedra that completed Phase I clinical trail for the treatment of pheochromocytoma in adults and neuroblastoma in children; Onalta, a Phase II clinical trail product for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors; and Solazed, a preclinical trail product for the treatment of malignant metastatic melanoma. The company was formerly known as Biostream, Inc. and changed its name to Molecular Insight Pharmaceuticals, Inc. in 2003.

Collegium Pharmaceutical's wisdom is in developing over-the-counter and prescription drugs for a variety of conditions affecting the skin and central nervous and respiratory systems. Typically the company starts with existing drugs and works to improve them through new delivery systems that modify their release, or prevent abuse. It is working with drugs to treat such conditions as fibromyalgia, pain, and sleep apnea. Through its subsidiary Onset Therapeutics, the company markets wound care and dermatology (acne, skin infections) drugs. Its topical aerosol product Exactacain is licensed and sold by Healthpoint while its approved allergy nasal spray AllerNaze is licensed to Lupin Ltd.

Soft Gel Technologies, Inc. company makes hermetically sealed gelatin encapsulations of dietary supplements -- vitamins, minerals, fatty acids, and herbal extracts. The company manufactures more than 150 products, both private label and branded, to promote digestive health, immune system support, urinary tract wellness, and weight loss. Its brands include Carnisol, Femalgen, GlucoFit, and LyCoQ. Soft Gel Technologies also provides contract research and development, formulation, manufacturing, and sales and marketing services for other nutritional products companies. Soft Gel company is owned by Japanese chemicals firm Kenko.

Minster Pharmaceuticals plc, through its subsidiary, Minster Research Limited, develops pharmaceutical compounds for the treatment of neurological and psychiatric conditions in the United Kingdom. Its products pipeline comprises Tonabersat, which is in Phase IIb clinical trial for the prevention and treatment of migraine; and Sabcomeline, a Phase IIa clinical trial product for the management of cognitive decline and negative symptoms in schizophrenia. The company is based in Saffron Walden, the United Kingdom.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.